- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00046722
Marijuana for HIV-Related Peripheral Neuropathy
June 12, 2007 updated by: Center for Medicinal Cannabis Research
Effects of Marijuana on Neuropathic Pain in HIV-Related Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study.
To evaluate whether smoked marijuana reduces pain in people with HIV-related peripheral neuropathy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study will include subjects with peripheral neuropathy caused either by HIV-disease or antiretroviral medication for the treatment of HIV.
A neurologist will conduct a neurological and pain evaluation to determine eligibility for the study.
Subjects who meet all eligibility criteria will be admitted to the General Clinical Research Center at San Francisco General Hospital for seven days.
Subjects will be randomized (like a toss of a coin) to smoke marijuana or a placebo (cigarettes with no THC).
Study Type
Interventional
Enrollment
50
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- University of California, San Francisco Community Consortium
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
INCLUSION CRITERIA:
- HIV positive.
- Be 18 years or older.
- Diagnosis of HIV-related painful neuropathy.
- Stable antiretroviral therapy or no antiretroviral therapy for at least 8 weeks.
- Prior use of marijuana, at least 6 occasions in their lifetime prior to enrollment.
EXCLUSION CRITERIA: (Not allowed)
- Current use of smoked tobacco products.
- Current methadone treatment.
- Use of smoked marijuana within 30 days of enrollment.
- Diagnosis of diabetes mellitus.
- Currently receiving treatment with corticosteroids.
- Use of INH, dapsone or metronidazole within 8 weeks prior to enrollment.
- Severe heart disease, uncontrolled high blood pressure or lung disease.
- Women who are pregnant or breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Change in level of HIV-related neuropathic pain as recorded on a 100mm Visual Analog Scale.
|
Secondary Outcome Measures
Outcome Measure |
---|
Change in level of experimentally-induced pain.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2003
Study Completion
April 1, 2005
Study Registration Dates
First Submitted
October 1, 2002
First Submitted That Met QC Criteria
October 2, 2002
First Posted (Estimate)
October 3, 2002
Study Record Updates
Last Update Posted (Estimate)
June 14, 2007
Last Update Submitted That Met QC Criteria
June 12, 2007
Last Verified
June 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C00-SF-101
- CC# 056
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Smoked Marijuana
-
Brown UniversityCompleted
-
Center for Medicinal Cannabis ResearchUniversity of California, San FranciscoTerminated
-
Bayliss J. Camp, PhDRecruitingDriving Impaired | Cannabis SmokingUnited States
-
Center for Medicinal Cannabis ResearchCompleted
-
Center for Medicinal Cannabis ResearchTerminated
-
University of Colorado, BoulderNational Institute on Drug Abuse (NIDA)RecruitingCannabis | Electroencephalography | MemoryUnited States
-
Center for Medicinal Cannabis ResearchCompletedMultiple SclerosisUnited States
-
Jamie BurrActive, not recruitingCannabis | Cardiovascular Risk FactorCanada
-
Guangxi Medical UniversityCompleted
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedMarijuana DependenceUnited States